Dr. Peter Dosa's Work Highlighted in Qlaris Bio Video
Oct. 19, 2021
This spring phase I/II clinical trials began for QLS-101: a novel prodrug developed by the ITDD's Dr. Peter Dosa in collaboration with Dr. Michael Fautsch of the Mayo Clinic. The licensee for the drug, Qlaris Bio, has now created a video to explain how the drug reduces the pressure inside the eye, with the hopes of providing relief to people with increased eye pressure. You can watch the video here.